Effect of the correction for noncompliance and contamination on the estimated reduction of metastatic prostate cancer within a randomized screening trial (ERSPC section Rotterdam)

International Journal of Cancer

Volumn 127, Issue 11, 2010, Pages 2639-2644

  Kerkhof, Melissa ^a   Roobol, Monique J ^a   Cuzick, Jack ^b   Sasieni, Peter ^b   Roemeling, Stijn ^a   Schröder, Fritz H ^a   Steyerberg, Ewout W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

contamination; metastases; noncompliance; prostate cancer; PSA screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER SCREENING; CLINICAL RESEARCH; CLINICAL TRIAL; CONTAMINATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PATIENT ATTITUDE; PATIENT COMPLIANCE; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; BLOOD; MASS SCREENING; METASTASIS; METHODOLOGY; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; NETHERLANDS; PATHOLOGY; PROSTATE TUMOR; STATISTICAL MODEL; STATISTICS;

AGED; HUMANS; INCIDENCE; MALE; MASS SCREENING; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM METASTASIS; NETHERLANDS; PATIENT COMPLIANCE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 78049492779     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25278     Document Type: Article

References (13)

1. Roobol M, Schroder F,. European Randomized Study of Screening for Prostate Cancer: achievements and presentation. BJU Int 2003; 92: 117-22.
2. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, et al.; ERSPC Investigators. Screening and prostate cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1351-4.
3. de Koning HJ, Liem MK, Baan CA, Boer R, Schroder FH, Alexander FE,. Prostate cancer mortality reduction by screening: power and time frame with complete enrollment in the European randomized screening for prostate cancer (ERSPC) trial. Int J Cancer 2002; 98: 268-73.
4. de Koning HJ, Auvinen A, Berenguer Sanchez A, Calais da Silva F, Ciatto S, Denis L, Gohagan JK, Hakama M, Hugosson J, Kranse R, Nelen V, Prorok PC, et al. Large-scale randomized prostate cancer screening trials: program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial. Int J Cancer 2002; 97: 237-44.
5. Cuzick J, Edwards R, Segnan N,. Adjusting for non-compliance and contamination in randomized clinical trials. Stat Med 1997; 16: 1017-29.
6. Duffy W, Cuzick J, Tabar L, Vitak B, Chen TH, Yen MF, Smith RA,. Correcting for non-compliance bias in case-control studies to evaluate cancer screening programmes. Appl Stat 2002; 51: 235-43.
7. Otto SJ, van der Cruijsen IW, Liem MK, Korfage IJ, Lous JJ, Schroder FH, de Koning HJ,. Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. Int J Cancer 2003; 105: 394-9.
8. Cuzick J,. Primary endpoints for randomised trials of cancer therapy. Lancet 2008; 371: 2156-8.
9. Roemeling S, Roobol MJ, Otto SJ, Habbema DF, Gosselaar C, Lous JJ, Cuzick J, Schroder FH,. Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trial. Prostate 2007; 67: 1053-60.
10. de Koning HJ, Blom J, Merkelbach JW, Raaijmakers R, Verhaegen H, van Vliet P, Nelen V, Coebergh JW, Hermans A, Ciatto S, Mäkinen T,. Determining the cause of death in randomized screening trial(s) for prostate cancer. BJU Int 2003; 92: 71-8.
11. Cuzick J, Sasieni P, Myles J, Tyrer J,. Estimating the effect of treatment in a proportional hazards model in the presence of non-compliance and contamination. J R Stat Soc B 2007; 69: 565-88.
12. Roobol M, Kerkhof M, Schroder F, Cuzick J, Sasieni P, Hakama M, Stenman U, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H,. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European randomised study of screening for prostate cancer (ERSPC). Eur Urol 2009; 56: 584-91.
13. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J,. Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer-results from a prospective population-based randomized controlled trial. Eur Urol 2007; 51: 659-64.